Is oral L‑glutamine effective for preventing or treating chemotherapy‑induced peripheral neuropathy, and what dosing regimen is recommended?

Oral L-Glutamine for Chemotherapy-Induced Peripheral Neuropathy

Oral L-glutamine is NOT recommended for preventing or treating chemotherapy-induced peripheral neuropathy (CIPN) in adults, as current ASCO guidelines explicitly state that no agents are recommended for CIPN prevention, and duloxetine remains the only evidence-based treatment for established painful CIPN. 1

Guideline-Based Recommendation

The 2020 ASCO Clinical Practice Guideline Update on CIPN management provides the definitive framework for this question. After reviewing 257 new references including 3 systematic reviews with meta-analyses and 28 primary prevention trials, the Expert Panel reconfirmed that no agents—including glutamine—are recommended for CIPN prevention 1. The European ESMO-EONS-EANO guidelines (2020) similarly note only "modest evidence for efficacy in children" with glutamine, explicitly stating "no recommendation is possible in adults" 2.

Why Glutamine Is Not Recommended Despite Some Positive Studies

While several older studies (2001-2007) showed potential benefit with glutamine:

• A 2007 study in oxaliplatin-treated colorectal cancer patients (n=86) found reduced grade 3-4 neuropathy with 15g twice daily 3
• Two studies in high-dose paclitaxel showed reduced dysesthesias, numbness, and motor weakness with 10g three times daily 4, 5

These findings have not been validated in larger, high-quality trials. A 2018 evidence-based appraisal concluded that despite showing reduced CIPN-induced pain (RR=0.26), the clinical efficacy does not justify the cost (approximately $17/day), and the authors explicitly recommend against routine use 6. More recent systematic reviews (2024-2025) do not include glutamine among effective pharmacological treatments 7, 8.

What Actually Works: The Evidence-Based Algorithm

For Prevention:

• No pharmacological agents are recommended 1
• Focus on chemotherapy dose modification when neuropathy develops
• Consider dose delays, reductions, substitutions, or stopping chemotherapy when patients develop intolerable neuropathy or functional impairment 1

For Established Painful CIPN:

1. First-line: Duloxetine - The only agent with appropriate evidence 1, 2

   • Dose: 30 mg/day for 1 week, then 60 mg/day 2
   • More effective for platinum-based than taxane-induced neuropathy 2
   • Benefit is moderate but proven in large randomized trials 1

2. Second-line options for pain control:

   • Venlafaxine: 50 mg initially, then 37.5 mg twice daily 2
   • Tricyclic antidepressants (amitriptyline): Starting 10-25 mg/day 2
   • Tramadol or strong opioids for refractory cases 2

3. Topical therapies:

   • 1% menthol cream twice daily to affected areas 2
   • Baclofen/amitriptyline/ketamine gel combinations 2

Critical Pitfalls to Avoid

• Do not prescribe glutamine based on older single-center studies - The evidence has not held up in systematic reviews and guideline evaluations
• Do not confuse the FDA-approved indication for L-glutamine - The drug label 9 shows approval only for sickle cell disease complications, NOT for CIPN
• Do not delay duloxetine initiation - It is the only proven pharmacological treatment for painful CIPN 1, 2
• Do not ignore non-pharmacological approaches - Low-to-moderate walking and resistance exercise during chemotherapy can reduce CIPN severity 10

Dosing Information (For Context Only, Not Recommended)

If glutamine were to be considered despite lack of guideline support, historical studies used:

• 15g twice daily (30g/day total) for oxaliplatin-induced neuropathy, starting on day of infusion for 7 consecutive days every 2 weeks 3
• 10g three times daily (30g/day total) for 4 days starting 24 hours after high-dose paclitaxel 4

However, this dosing information is provided only for historical context—glutamine should not be prescribed for CIPN in routine clinical practice based on current evidence 1, 6.